Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
nitrate and fluoride · 1 trial · 1 indication
The examiner indicated the participant's response to an evaporaitve air stimulus for each tooth using the Schiff Sensitivity Scale scored as follows - 0: Participant does not respond to air stimulation; 1: responds to air stimulus but does not request discontinuation of stimulus; 2: Participant responds to air stimulus and requests discontinuation or moves from stimulus; 3: Participant responds to stimulus, considers stimulus to be painful, and requests discontinuation of the stimulus. A reduction in Schiff Sensitivity score is indicative of an imrpovement in sensitivity.
| Arm | Type | Description |
|---|---|---|
| Potassium nitrate and sodium fluoride | EXPERIMENTAL | 3.0% weight by weight (w/w) potassium nitrate mouthwash with 0.02% sodium fluoride |
| Standard fluoride dentifrice | OTHER | Standard fluoride dentifrice containing 1000 ppm fluoride as sodium monofluorophosphate (SMFP) |
| Name | Type | Description |
|---|---|---|
| Potassium nitrate and sodium fluoride | DRUG | 3.0% w/w potassium nitrate mouthwash with 0.02% sodium fluoride |
| Standard fluoride dentifrice | DRUG | Standard fluoride dentifrice containing 1000 ppm fluoride as SMFP |
Inclusion Criteria: * Participants in good general health, with self-reported history of dentinal hypersensitivity lasting more than 6 months but not more than 10 years. * Participants with minimum of 20 natural teeth. * At screening, a minimum of four, non-adjacent teeth. 1. Teeth showing signs...
Nitrate is an investigational small molecule being developed by GSK plc for the treatment of dentin sensitivity, also known as dentinal hypersensitivity or dentin hypersensitivity. It is being studied for its ability to reduce dental pain associated with these conditions.
Nitrate is being developed by GSK plc, a pharmaceutical company traded on the London Stock Exchange under the ticker GSK. The drug is currently in clinical development for dentin sensitivity and related hypersensitivity conditions.
Nitrate is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials have been completed, but the drug remains in early-stage development for dentin hypersensitivity.
Nitrate has been studied in three completed clinical trials. NCT01587950 was a Phase 1 study with 12 participants, NCT02226562 was a Phase 2 study with 191 participants, and NCT03943095 was a Phase 2 study with 123 participants, all evaluating its effects on dentin hypersensitivity.
Nitrate is being studied in formulations that include potassium nitrate, as indicated by the clinical trial NCT01587950, which evaluated the effects of potassium nitrate in reducing dentinal hypersensitivity. However, Nitrate as a drug asset may refer to the active ingredient or the product.